Q-omics provides the consensus-scored IGKV6-21 profile across patient tissues and cancer cell-line models. IGKV6-21 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, IGKV6-21 is differentially expressed in 7, with the highest sampling consensus in COAD. Additionally, IGKV6-21 RNA expression shows 8,620 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight HNSC, COAD, and LSCC as cancer lineages where IGKV6-21 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for IGKV6-21 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes IGKV6-21 survival associations across molecular data types. IGKV6-21 RNA expression shows survival associations in the most cancer types (22), followed by mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible IGKV6-21 RNA expression–survival associations across cancer types. High IGKV6-21 expression shows favorable associations in HNSC, UCEC, SKCM, BRCA, COAD and MESO. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for IGKV6-21 RNA expression.
This table summarizes IGKV6-21 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7, while mass-spec protein shows differences in 4. The strongest signals are observed in COAD for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for IGKV6-21. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. IGKV6-21 shows lower tumor expression in COAD, BRCA, LIHC and READ and higher tumor expression in LUAD and KIRC. The COAD box plot shows higher IGKV6-21 RNA expression in normal versus tumor tissue (log2 FC = −4.164, t-test p < 0.001).
This table shows molecular features associated with IGKV6-21 in patient tissues and cancer cell lines. In patient samples, IGKV6-21 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set.
